Each year, health authorities make predictions about which flu strains will be the most common. But if the strains mutate, flu vaccines are powerless to prevent infection. Enter VaxInnate, which is taking its quick-to-produce quadrivalent seasonal flu vaccine into Phase II safety trials.
The U.S. Department of Health and Human Services apparently likes what it's seen from a 5-year contract with VaxInnate. Its Biomedical Advanced Research and Development Authority (BARDA) has extended the contract's base period with the flu vaccine maker, a move that allows for the use of $53 million.
VaxInnate's VAX161, the company's vaccine in development to protect against a bird flu pandemic, has moved into Phase I trials.
"VaxInnate: We're fast, cheap and easy," jokes CSO Alan Shaw (pictured, left). And that's just what the HHS likes about the company. Last month the agency granted the Cranbury,...
Earlier this week, the HHS doubled down on new vaccine technology. The government granted Maryland-based Novavax a contract worth up to $179.1 million, while Cranbury, NJ's VaxInnate picked up a
The feds drive to whip up a bigger, faster supply of flu vaccine to fight pandemics has triggered a pair of new contracts initially totaling $215 million for Novavax and VaxInnate. Novavax shares
The Wellcome Trust has signed on as a new investor of VaxInnate, leading a $30 million Series D for the vaccine developer as it pursues a more efficient approach to the field. New Leaf Venture
VaxInnate's universal flu vaccine has produced positive results in an early stage trial at the University of Texas at Galveston. Researchers there said that VaxInnate's M2e universal vaccine